Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Leiomyosarcoma × Clear all

Phase

Phase 2 10 Phase 1 5 Phase 3 4 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Neoplasms 21 Neoplasm Metastasis 18 Breast Neoplasms 18 Prostatic Neoplasms 14 Stomach Neoplasms 12 Recurrence 12 Colorectal Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 10 Pancreatic Neoplasms 10 Ovarian Neoplasms 10 Lung Neoplasms 10 Head and Neck Neoplasms 10 Myasthenia Gravis 9 Carcinoma, Hepatocellular 9 Urinary Bladder Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Melanoma 7 Leukemia, Myeloid, Acute 7 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Follicular 5 Liver Neoplasms 5 Glioblastoma 5 Colonic Neoplasms 5 Carcinoma, Transitional Cell 5 Small Cell Lung Carcinoma 4 Myelodysplastic Syndromes 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

PTC596 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05269355 2025-06-13

SUNRISELMS

PTC Therapeutics

Phase 2/3 Terminated

359 enrolled 15 charts

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡